New combo therapy aims to stop liver cancer from coming back after surgery
NCT ID NCT07522411
First seen Apr 24, 2026 · Last updated May 14, 2026 · Updated 4 times
Summary
This study tests whether giving a combination of drugs (sintilimab, bevacizumab, and chemotherapy) before surgery can lower the chance of liver cancer returning in patients at high risk. About 100 adults with resectable liver cancer and high-risk features will be randomly assigned to either the drug combo followed by surgery, or surgery alone. The main goal is to see if the combo improves the 2-year recurrence-free survival rate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.